Oncology “First Launch” and Partnering

1:45 PM–2:45 PM Jun 5, 2019 (US - Eastern)

105AB, Level 100


With multiple oncology "first launch" successes in recent years, most oncology emerging pharma company boards and executive teams will consider this increasingly attractive path to commercialization, often in parallel to partnering.

Data shared during this panel, from all US oncology emerging pharma "first launches," will support discussion topics including: US, EU and RoW first launch benchmarks, preparing to launch vs exit or co-promote, special challenges in personalized medicine, rare oncology indications and "novel" technologies and innovation in “first launches” (customer experience, multi-channel commercial models and the role of analytics, AI and machine learning).

Ability Level: All

Session ID: 503523